Previous 10 | Next 10 |
ALENA DZIHILEVICH/iStock via Getty Images Vir Biotechnology (VIR) perks up 3% premarket after announcing new data from its ongoing Phase 2 clinical trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus ((HBV)) infection. The results,...
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents – – Management to host conference call today, Friday, June 25, 2021, at 11:00 a.m. ET ...
4 Top Health Care Stocks To Add To Your Watchlist This Week Health care stocks have been in focus in the stock market over the past year for obvious reasons. Everyone was taken aback as we were plagued by the global pandemic. However, every crisis presents a new opportunity. Fun...
Dr_Microbe/iStock via Getty Images Several combinations of antibody therapies were effective against many COVID-19 variants currently in circulation, a mice and hamster study conducted by the Washington University School of Medicine in St. Louis indicates, according to Reuters. The scien...
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announce final, confirmatory results from Phase 3 COMET-ICE trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalization or death among high-risk adult outpatients wi...
– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease – – U.S. National Institutes o...
AstraZeneca (AZN) announces that its antibody cocktail, AZD7442, didn’t achieve a statistically significant reduction in the risk of symptomatic COVID-19 after exposure to the virus, failing to meet primary endpoint of the STORM CHASER trial.The trial included 1,121 participants of age...
SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Study of the Li...
SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9th at 12:...
Vir Biotechnology (NASDAQ: VIR) isn't first to cross the finish line with its antibody treatment for COVID-19. In fact, with its recent Emergency Use Authorization (EUA), it joins two much bigger players. The U.S. Food and Drug Administration earlier granted EUAs to Eli Lilly an...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...